Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: May 9, 2025
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025
Read more at globenewswire.com
